Larimar Therapeutics, Inc.
LRMR Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$2.39
KIRA · Stoqly’s AI analyst, in plain words
- Larimar Therapeutics, Inc. lost $166M in fiscal 2025.
- Free cash flow was −$113M in fiscal 2025, — of revenue.
Market cap
—
P/E
—
Revenue
—
Net income
−$166M
Free cash flow
−$113M
Operating margin
—
Larimar Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$166M
No. It lost money last year.
What Larimar Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- Larimar Therapeutics, Inc.
- CIK
- 0001374690
Larimar Therapeutics, Inc. · LRMR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$50.6M | −$35.4M | −$36.9M | −$80.6M | −$166M |
| Diluted EPS | −$2.95 | −$1.37 | −$0.84 | −$1.32 | — |
| Cash | |||||
| Cash from operations | −$42.1M | −$27.6M | −$33.5M | −$70.8M | −$113M |
| Capital expenditure | $0.3M | $0.1M | $0.2M | $0.5M | $0.1M |
| Free cash flow | −$42.4M | −$27.7M | −$33.6M | −$71.3M | −$113M |
| Share count change | 44.4% | 50.1% | 70.4% | 39.5% | — |
| Debt and strength | |||||
| Cash and short-term investments | $70.1M | $118M | $86.8M | $183M | $137M |
| Shareholders' equity | $64.4M | $111M | $81.7M | $172M | $78.1M |
| Current ratio | 8.2x | 11.3x | 9.5x | 8.0x | 2.2x |
| Returns and quality | |||||
| Return on equity | −65.7% | −40.3% | −38.4% | −63.6% | −132.6% |
| Return on tangible equity | −78.6% | −31.9% | −45.2% | −46.9% | −212.2% |
| Altman Z'' | 0.9 | 7.4 | 2.2 | 4.5 | −13.0 |
Insiders bought, 12 months
$25.7M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Larimar Therapeutics, Inc. · LRMR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.39 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001374690). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.